Skip to main content
Top
Published in: Journal of General Internal Medicine 2/2011

01-02-2011 | Perspectives

Personalized Medicine: Understanding Probabilities and Managing Expectations

Authors: Zachary Laksman, MD, Allan S. Detsky, MD, PhD

Published in: Journal of General Internal Medicine | Issue 2/2011

Login to get access

ABSTRACT

Personalized medicine promises to represent a transformation in clinical care that will be ushered in by the unprecedented growth and development in the field of human genetics. Further examination of the scientific foundations of this new hope reveals a great number of challenges that lie ahead. While basic science research feverishly races to produce solutions, we continue to wait for the translation of deliverables. Products that have and will come to market may leave our clinical communities and systems exposed and unprepared. At each step, from basic science research to infrastructure development, a great deal of creativity and investment are required before the arsenal of more personalized tools can be assimilated into our current models of health care. This commentary seeks to share perspectives on the current status of personalized medicine from the vantage point of several potential investors, and integrate them into a common set of goals and understanding. We conclude that the stylized model of personalized medicine is more akin to a marketing tool than a literal prediction of the future.
Literature
1.
go back to reference Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex disease. Nature. 2009;461(7265):747–53.CrossRefPubMed Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex disease. Nature. 2009;461(7265):747–53.CrossRefPubMed
2.
3.
go back to reference Xavier RJ, Rioux JD. Genome-wide association studies: a new window into immune mediated diseases. Nature Reviews. Immunology. 2008;(8):631–43. Xavier RJ, Rioux JD. Genome-wide association studies: a new window into immune mediated diseases. Nature Reviews. Immunology. 2008;(8):631–43.
4.
go back to reference Attia J, Ioannidis PA, Thakkinstian A, et al. How to use an article about genetic association: C: what are the results and will they help me in caring for my patients? JAMA. 2009;301(3):304–08.CrossRefPubMed Attia J, Ioannidis PA, Thakkinstian A, et al. How to use an article about genetic association: C: what are the results and will they help me in caring for my patients? JAMA. 2009;301(3):304–08.CrossRefPubMed
5.
go back to reference Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl JMed. 2010;363:166–76.CrossRef Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl JMed. 2010;363:166–76.CrossRef
6.
go back to reference Collins C, Purohit R, Podolsky H, et al. The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. Vasc Pharmacol. 2006;45:258–67.CrossRef Collins C, Purohit R, Podolsky H, et al. The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. Vasc Pharmacol. 2006;45:258–67.CrossRef
7.
8.
go back to reference Lesko LJ. Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther. 2007;81(6):807–16.CrossRefPubMed Lesko LJ. Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther. 2007;81(6):807–16.CrossRefPubMed
9.
go back to reference Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095–106.CrossRefPubMed Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095–106.CrossRefPubMed
10.
go back to reference McWilliam A, Lutter R, Nardinelli C. "Health Care Savings from Personalizing Medicine Using Genetic Testing: The Case of Warfarin." 2006 AEI-Brookings Joint Center. Working paper 06-23. November 2006. McWilliam A, Lutter R, Nardinelli C. "Health Care Savings from Personalizing Medicine Using Genetic Testing: The Case of Warfarin." 2006 AEI-Brookings Joint Center. Working paper 06-23. November 2006.
11.
go back to reference Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116:2563–70.CrossRefPubMed Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116:2563–70.CrossRefPubMed
12.
go back to reference Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753–64.CrossRefPubMed Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753–64.CrossRefPubMed
13.
go back to reference Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmcoeconomics. 2010;28(1):61–74.CrossRef Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmcoeconomics. 2010;28(1):61–74.CrossRef
14.
go back to reference Paikin JS, Eikelboom JW, Cairns JA, Hirsch J. New antithrombotic agents-insights from clinical trials. Nature Reviews Cardiology. 2010,online. Paikin JS, Eikelboom JW, Cairns JA, Hirsch J. New antithrombotic agents-insights from clinical trials. Nature Reviews Cardiology. 2010,online.
15.
16.
go back to reference Su Z, Gulick RM, Krambrink A, et al. Response to vicriviroc in treatment experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of Aids clinic trials group A5211. J Infect Dis. 2009;200(11):1724–8.CrossRefPubMed Su Z, Gulick RM, Krambrink A, et al. Response to vicriviroc in treatment experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of Aids clinic trials group A5211. J Infect Dis. 2009;200(11):1724–8.CrossRefPubMed
18.
go back to reference Wu AC, Fuhlbrigge AL. Economic evaluation of pharmacogenetic tests. Pharmacol Ther. 2008;84(2):272–4.CrossRef Wu AC, Fuhlbrigge AL. Economic evaluation of pharmacogenetic tests. Pharmacol Ther. 2008;84(2):272–4.CrossRef
Metadata
Title
Personalized Medicine: Understanding Probabilities and Managing Expectations
Authors
Zachary Laksman, MD
Allan S. Detsky, MD, PhD
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 2/2011
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-010-1515-6

Other articles of this Issue 2/2011

Journal of General Internal Medicine 2/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine